V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10446560 | 10041962 | 1.82 | 63 | 03 | 2021-12-16 | 2021-12-16 | Apalutamide | 02 | N | RITUXIMAB + VENETOCLAX | 101053470 |
| 10446597 | 10041963 | 1.68 | 108.4 | Palliative (P) | null | 2017-05-05 | Nilotinib | null | N | CISPLATIN + ETOPOSIDE | 100533160 |
| 10446651 | 10041964 | 1.84 | 85.5 | Palliative (P) | 2016-08-30 | 2016-09-15 | Letrozole + Palbociclib | 02 | Y | OXALIPLATIN + MDG | 100762197 |
| 10446774 | 10041966 | 1.8 | 92.55 | Curative (C) | null | 2017-08-29 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | N | null | CAPECITABINE + CISPLATIN + EPIRUBICIN | 100027111 |
| 10446841 | 10041967 | 1.69 | null | Curative (C) | null | 2020-04-28 | null | null | N | CTD | 100546432 |
| 10446855 | 10041968 | 1.79 | 78.7 | Palliative (P) | null | 2018-06-26 | LENVATINIB | null | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101047923 |
| 10447006 | 10041969 | 1.77 | 57.3 | Palliative (P) | 2019-06-17 | 2019-06-17 | Irinotecan + Modified De Gramont | 02 | N | BENDAMUSTINE + OBINUTUZUMAB | 100738753 |
| 10447146 | 10041972 | 1.78 | 80.1 | null | 2021-12-19 | 2022-01-02 | RIALTO TRIAL | 02 | null | IXAZOMIB | 100066310 |
| 10447365 | 10041974 | 1.5 | 91 | Palliative (P) | null | 2018-01-03 | CISPLATIN + ETOPOSIDE | N | N | NAB-PACLITAXEL | 100578787 |
| 10447501 | 10041975 | 1.68 | 97.7 | Curative (C) | 2018-04-13 | 2018-04-20 | Panitumumab +Oxaliplatin +MdG | 02 | null | CVD | 101696087 |
| 10447622 | 10041976 | 1.54 | 152.6 | 03 | null | 2020-04-21 | AVELUMAB + AXITINIB | null | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 101525337 |
| 10447630 | 10041977 | 1.77 | 0 | Palliative (P) | 2017-03-19 | 2017-03-28 | Obinutuzumab +CVP | 02 | N | IDELALISIB + RITUXIMAB | 101196709 |
| 10447690 | 10041978 | 1.75 | 95.7 | Palliative (P) | 2019-06-23 | 2019-06-28 | ABEMACICLIB + FULVESTRANT | 02 | N | MYELOMA XII TRIAL | 100413450 |
| 10447813 | 10041979 | 1.8 | 92.55 | Palliative (P) | 2018-01-13 | 2018-01-13 | Bortezomib + CYCLOPHOSPHAMIDE | null | N | LUTETIUM-177 | 100270622 |
| 10448026 | 10041982 | 1.64 | 78.4 | null | 2021-12-08 | 2021-12-08 | CYTARABINE + ETOPOSIDE | 02 | null | TRASTUZUMAB | 100036696 |
| 10448181 | 10041986 | 0 | 49.4 | 03 | null | 2018-08-04 | Carboplatin+Fluorouracil 4 or 5 day | null | N | RIALTO TRIAL | 100104010 |
| 10448183 | 10041987 | 1.73 | 84 | 03 | null | 2018-05-17 | Cisplatin + Pemetrexed | 01 | null | DOXORUBICIN EMBOLISATION | 100469644 |
| 10448360 | 10041991 | 1.72 | 60.9 | Palliative (P) | 2017-05-12 | 2017-06-09 | Ixazomib | N | null | CARDAMON TRIAL | 101425590 |
| 10448389 | 10041992 | 1.75 | 60 | Neo-adjuvant (N) | 2018-03-07 | 2018-03-15 | Cyclophosphamide + Etoposide (PO) | 02 | N | BORTEZOMIB + DARATUMUMAB | 100532477 |
| 10448427 | 10041993 | 1.83 | 90.3 | Palliative (P) | null | 2018-10-26 | Etoposide oral | N | N | PIXANTRONE | 100597119 |
| 10448603 | 10041994 | 1.73 | 52 | Palliative (P) | null | 2018-01-03 | ATEZOLIZUMAB + BEVACIZUMAB | null | N | ATEZOLIZUMAB | 100765545 |
| 10448673 | 10041995 | 1.75 | 78 | Palliative (P) | 2020-09-29 | 2020-09-29 | Cetuximab + FOLFIRI cycle 2 onwards | null | null | ATEZOLIZUMAB | 100667505 |
| 10448757 | 10041997 | 0 | null | Palliative (P) | 2016-10-25 | 2016-11-09 | THALIDOMIDE | 02 | N | IDELALISIB + RITUXIMAB | 100688522 |
| 10448803 | 10041998 | 1.6 | 78.6 | Curative (C) | 2020-04-03 | 2020-04-04 | Cytarabine High Dose | null | N | RALTITREXED | 100983818 |
| 10448947 | 10041999 | 1.8 | 55 | null | 2017-03-02 | 2017-03-10 | GemCarbo Days 1+8 | 1 | N | AVELUMAB + AXITINIB | 101169550 |
| 10449077 | 10042003 | null | null | Palliative (P) | 2018-12-29 | 2019-01-05 | null | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101099863 |
| 10449158 | 10042005 | 1.89 | 76.6 | Adjuvant (A) | 2019-07-12 | 2019-07-14 | null | 02 | N | FULVESTRANT + PALBOCICLIB | 100117413 |
| 10449209 | 10042006 | 1.85 | 90.9 | Adjuvant (A) | null | 2018-03-06 | null | null | N | FCR | 100307728 |
| 10449359 | 10042009 | 1.78 | 68 | null | 2022-04-05 | 2022-04-18 | Carboplatin+Fluorouracil 4 or 5 day | 02 | null | NILOTINIB | 100483399 |
| 10449361 | 10042010 | 1.68 | 82.5 | Disease modification (D) | 2017-06-23 | 2017-06-23 | Melphalan IV High dose | 02 | N | LENALIDOMIDE + RITUXIMAB | 101620296 |
| 10449493 | 10042011 | null | 108.8 | Palliative (P) | 2018-01-20 | 2018-01-26 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | null | ABEMACICLIB + FULVESTRANT | 100618672 |
| 10449531 | 10042013 | 1.73 | 62 | Palliative (P) | 2019-03-08 | 2019-03-09 | BEP 5 Day | 02 | N | IRINOTECAN + MDG | 101430794 |
| 10449561 | 10042015 | 1.76 | 53.4 | 03 | 2020-01-14 | 2020-01-14 | null | 02 | N | VINBLASTINE | 100469931 |
| 10449977 | 10042018 | 1.79 | 77.3 | Neo-adjuvant (N) | 2018-01-04 | 2018-01-19 | Apalutamide | 02 | N | CAPECITABINE + CISPLATIN + EPIRUBICIN | 101325616 |
| 10450064 | 10042019 | 1.6 | null | Neo-adjuvant (N) | 2018-09-10 | 2018-09-10 | Ribociclib | 02 | N | FEC | 100574858 |
| 10450089 | 10042021 | 1.6 | 62 | Palliative (P) | 2019-03-10 | 2019-03-29 | INTERLACE TRIAL | 02 | N | IDELALISIB + RITUXIMAB | 101036602 |
| 10450327 | 10042022 | 1.57 | 0 | null | 2021-01-22 | 2021-02-02 | FLAIR trial | 2 | N | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | 100638667 |
| 10450328 | 10042023 | 0 | 56.8 | Neo-adjuvant (N) | null | 2017-11-15 | ANAGRELIDE | N | N | GDP | 101584866 |
| 10450399 | 10042024 | 0 | null | Palliative (P) | 2018-12-09 | 2018-12-09 | CHLVPP | 02 | N | FCR | 100573677 |
| 10450454 | 10042025 | 1.62 | 77.4 | Palliative (P) | 2018-04-18 | 2018-04-19 | Brentuximab Vedotin | 02 | N | TRASTUZUMAB EMTANSINE | 101208450 |
| 10450586 | 10042028 | 1.79 | 69 | Palliative (P) | null | 2022-05-28 | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN | N | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101566166 |
| 10450635 | 10042029 | 1.85 | 67 | Curative (C) | 2018-06-24 | 2018-06-30 | Nilotinib | 02 | N | CLARITY TRIAL | 100032113 |
| 10450664 | 10042030 | 1.93 | 79.6 | Palliative (P) | 2019-12-09 | 2019-12-29 | Sorafenib | 02 | N | ECF | 100421788 |
| 10450685 | 10042031 | 1.72 | 81.2 | Palliative (P) | 2020-02-06 | 2020-02-13 | EVEROLIMUS | 2 | null | DOXORUBICIN EMBOLISATION | 101812935 |
| 10450881 | 10042033 | 1.66 | 78 | null | 2021-02-14 | 2021-02-16 | Oxaliplatin + Modified de Gramont | 02 | null | NILOTINIB | 100474062 |
| 10450987 | 10042034 | 1.63 | 72.9 | Palliative (P) | 2020-09-28 | 2020-09-28 | null | 02 | N | TRANSPLANT ALEMTUZUMAB + CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 100912151 |
| 10451065 | 10042035 | 1.71 | 101.7 | null | 2021-01-30 | 2021-02-09 | null | 02 | null | CVD | 100437216 |
| 10451277 | 10042036 | 1.53 | 63.8 | Curative (C) | 2020-05-22 | 2020-05-22 | BLEOMYCIN | 02 | N | METHOTREXATE | 101694524 |
| 10451348 | 10042037 | 1.72 | 57.7 | Disease modification (D) | 2017-09-24 | 2017-09-29 | Fulvestrant + Palbociclib | 02 | null | MELPHALAN | 100930720 |
| 10451415 | 10042038 | 1.63 | 93.3 | Palliative (P) | 2019-08-17 | 2019-08-17 | EOX | 02 | Y | FEC | 101502504 |